

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 July 2025 (03.07.2025)



(10) International Publication Number
WO 2025/140533 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 3/10 (2006.01)
A61K 31/437 (2006.01) A61P 25/28 (2006.01)
A61P 1/06 (2006.01)

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/CN2024/143125

(22) International Filing Date:

27 December 2024 (27.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/142183
27 December 2023 (27.12.2023) CN
PCT/CN2024/082373
19 March 2024 (19.03.2024) CN
PCT/CN2024/110158
06 August 2024 (06.08.2024) CN
PCT/CN2024/122957
30 September 2024 (30.09.2024) CN
PCT/CN2024/136524
03 December 2024 (03.12.2024) CN

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with information concerning incorporation by reference of
missing element or part (Rule 20.6)

(71) Applicant: **INSILICO MEDICINE IP LIMITED**
[CN/CN]; 26th Floor, Three Exchange Square, 8 Connaught
Place Central, Hong Kong (CN).

(72) Inventors: **DING, Xiao**; Suite 901, Tower C, Chang-
tai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai
201203 (CN). **YU, Huaxing**; Suite 901, Tower C, Chang-
tai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai
201203 (CN). **REN, Feng**; Suite 901, Tower C, Chang-
tai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai
201203 (CN). **WAN, Jianfei**; Suite 901, Tower C, Chang-
tai Plaza, 2889 Jinke Road, Pudong New Area, Shang-
hai 201203 (CN). **ZHANG, Haoyu**; Suite 901, Tower
C, Changtai Plaza, 2889 Jinke Road, Pudong New Area,
Shanghai 201203 (CN). **CHEN, Yi-Jang**; No 333, Section
1, Keelung Rd, Xinyi Dist, 110, Taipei, Taiwan (CN).

(74) Agent: **ZHONGZI LAW OFFICE**; 7F, New Era Building,
26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: NOVEL COMPOUNDS AS GLP-1R AGONISTS AND USES THEREOF

(57) Abstract: Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject
compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

WO 2025/140533 A1